Interestingly, we also showed that genetic mutation of PLOD1/2/3, which is present in ~3% of ccRCC patients, was associated with significantly poorer prognosis compared with wild-type PLOD1/2/3. Here, PLOD1 is linked to nonpapillary renal cell carcinoma.